Brochure
18 Oct 2024
Daewoong Bio Bioplant Promotion Brochure
PDF 10.0 MB
It contains an overall introduction to Daewoong Bio's bio plant's milestones, manufacturing facilities, and production capacity.
Content provided by our supplier
Daewoong Pharmaceutical Co.,Ltd
-
Country/Region:Korea, Republic Of
-
On CPHI since:2015
-
Employees:1000 - 4999
Company types
Primary activities
Other Content from Daewoong Pharmaceutical Co.,Ltd (2)
-
Video DAEWOONG PR VIDEO (EN)
We continue to take the initiative by making bold challenges and investments in R&D to leap forward as a global healthcare group. Following the 2022 launch of Fexuclue, a drug treating gastroesophageal reflux disease, the company released Envlo, a Type 2 diabetes treatment. By bolstering its R&D pipeline, Daewoong Pharmaceutical is developing first-in-class and best-in-class drugs.